Latest News
- Psoriasis
Monday, April 09, 2018
Ortho Dermatologics’ DUOBRII Improves Psoriasis Symptoms As Early As Two Weeks
DUOBRII (halobetasol propionate and tazarotene) (IDP-118) lotion demonstrated significant superiority over vehicle as early as two weeks, according to new research in Journal of the American Academy o…
Read the full storyWednesday, April 04, 2018
GlobalData: Sun Pharma’s Ilumya To Face Strong Competition in the US market
It’s a tough road ahead for Sun Pharma’s newly approved Ilumya, according to a new report from GlobalData, a leading data and analytics company. In March 2018 the US Food and Drug…
Read the full storyFriday, March 30, 2018
Escalier Biosciences Closes Financing, Focuses on Psoriasis
Escalier Biosciences BV, a privately held biopharmaceutical company, this month closed $19 million Series B financing. The round was led by Forbion with existing investors New Science Ventur…
Read the full storyTuesday, March 27, 2018
Skin of Color Society Reports Banner Year
Kudos to the Skin of Color Society (SOCS) for a banner year. At its recent annual business meeting held in conjunction with the 2018 Annual Meeting of the American Academy of Dermatology, SOCS…
Read the full storyThursday, March 22, 2018
FDA Approves Label Update for Cimzia Addressing Low Risk of Fetal Exposure
The FDA has approved a label update that includes pharmacokinetic data showing negligible to low transfer of Cimzia® (certolizumab pegol) through placenta and minimal transfer to …
Read the full story
Wednesday, March 21, 2018
Sun Pharma: FDA Approves Ilumya for Adult Psoriasis
The FDA has approved Ilumya™ (tildrakizumab-asmn) from Sun Pharma for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Il…
Read the full storyFriday, March 09, 2018
White Paper: It’s Time to Start Prescribing Biosimilars
The American College of Rheumatology’s new white paper, “The Science Behind Biosimilars -- Entering a New Era of Biologic Therapy,” encourages physicians to begin integrating biosi…
Read the full storyThursday, March 01, 2018
Calling All Students: Ortho Dermatologics Now Accepting Applications for the 2018 Aspire Higher Scholarship Program
Ortho Dermatologics is accepting applications for the 2018 Aspire Higher scholarship program for students who have been affected by dermatologic conditions. Through the program, nine students will …
Read the full storyFriday, February 16, 2018
Ortho Dermatologics Presents Analysis of Siliq Phase 3 Data on Disease-Related Anxiety and Depression in Patients with Psoriasis
Ortho Dermatologics, a division of Valeant Pharmaceuticals North America, LLC, shared the results from an analysis of the Phase 3 clinical trial AMAGINE-1, which evaluated mental health comorbidities …
Read the full storyFriday, February 16, 2018
Stelara Reduces Aortic Vascular Inflammation
In addition to its effects on skin inflammation, Stelara (Ustekinumab) reduces aortic inflammation, report researchers from the Perelman School of Medicine at the University of Pennsylvania …
Read the full story
Thursday, February 15, 2018
Lilly: New Taltz Data and Pipeline Update to be Presented at AAD Annual Meeting
Eli Lilly and Company will present new data for Taltz® (ixekizumab), baricitinib, and mirikizumab at the American Academy of Dermatology (AAD) annual meeting in San Diego. The data include…
Read the full story
Wednesday, February 14, 2018
FDA Accepts Ortho Dermatologics' NDA For Jemdel Plaque Psoriasis Treatment
The FDA has accepted the New Drug Application for Jemdel (halobetasol propionate 0.01%) (IDP-122) lotion from Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. If approved…
Read the full storyThursday, February 08, 2018
FDA Approves Cosentyx Label Update to Include Scalp Psoriasis
The FDA has approved a label update for Novartis' Cosentyx (secukinumab), the first interleukin-17A (IL-17A) antagonist approved to treat moderate to severe plaque psoriasis. The updated label inc…
Read the full storyMonday, January 15, 2018
Cochrane Review: Biologics Trump Other Systemics for Pso
Biologics appear to be the most effective systemic medicines for achieving a chronic plaque psoriasis score of PASI (Psoriasis Area and Severity Index) 90, according to a newly published Cochrane Revi…
Read the full storyThursday, December 21, 2017
UCB: Bimekizumab Shows Joint and Skin Responses in Psoriatic Arthritis
UCB has announced that the Phase 2b BE ACTIVE study met the primary objective of establishing dose response for bimekizumab with statistical significance. The study also demonstrated robust efficacy i…
Read the full story
